Phase Ia/Ib study for Saftey, Tolerability, Pharmacokinetics, pharmacodynamics and efficacy of recombinant human anti-VEGFR-2 antibody(JY025) in patients with advanced, recurrent or metastatic solid tumor
Latest Information Update: 03 Oct 2019
At a glance
- Drugs Ranibizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Beijing Eastern Biotech
Most Recent Events
- 03 Oct 2019 New trial record